Lupin reports Q4FY21 consolidated PAT of Rs. 460.36 Cr
It reported total income of Rs.15299.25 crores during the FY ended March 31, 2021
It reported total income of Rs.15299.25 crores during the FY ended March 31, 2021
The additional allocation of Tocilizumab will ensure sufficient availability for COVID-19 patients and augment the government’s efforts to fight the pandemic
The INVANZ brand and generic market had U.S. sales of approximately US $205 million MAT for the most recent twelve months ending March 2021 according to IQVIA Health
The Department of Pharma has allocated this drug amongst the states/UTs based on expected supply that will be available from May 10 to May 31, 2021
The rating withdrawal is based on the company’s request and in line with CRISIL Rating’s policy on withdrawal of ratings.
Alembic has reported total income of Rs.83.79 crores during the FY ended March 31, 2021
Jubilant successfully challenged Bracco's patent infringement claims in an Inter Parties Review (IPR) proceeding before the U.S. Patent Office
Glucon-D, Sugar Free, EverYuth Scrub, Peel Off Face Mask and Nycil maintained their leadership positions in-their respective categories as on March 2021.
The drug accumulates in the virus infected cells and prevents virus growth by stopping viral synthesis and energy production
State governments and UTs have been asked to monitor proper distribution within the state/UT covering government and private hospitals
Subscribe To Our Newsletter & Stay Updated